Literature DB >> 9662404

Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I.

D S Geller1, J Rodriguez-Soriano, A Vallo Boado, S Schifter, M Bayer, S S Chang, R P Lifton.   

Abstract

Pseudohypoaldosteronism type I (PHA1) is characterized by neonatal renal salt wasting with dehydration, hypotension, hyperkalaemia and metabolic acidosis, despite elevated aldosterone levels. Two forms of PHA1 exist. An autosomal recessive form features severe disease with manifestations persisting into adulthood. This form is caused by loss-of-function mutations in genes encoding subunits of the amiloride-sensitive epithelial sodium channel (ENaC; refs 2,3). Autosomal dominant or sporadic PHA1 is a milder disease that remits with age. Among six dominant and seven sporadic PHA1 kindreds, we have found no ENaC gene mutations, implicating mutations in other genes. As ENaC activity in the kidney is regulated by the steroid hormone aldosterone acting through the mineralocorticoid receptor, we have screened the mineralocorticoid receptor gene (MLR) for variants and have identified heterozygous mutations in one sporadic and four dominant kindreds. These include two frameshift mutations (one a de novo mutation), two premature termination codons and one splice donor mutation. These mutations segregate with PHA1 and are not found in unaffected subjects. These findings demonstrate that heterozygous MLR mutations cause PHA1, underscore the important role of mineralocorticoid receptor function in regulation of salt and blood pressure homeostasis in humans and motivate further study of this gene for a potential role in blood pressure variation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662404     DOI: 10.1038/966

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  53 in total

1.  Functional expression of a pseudohypoaldosteronism type I mutated epithelial Na+ channel lacking the pore-forming region of its alpha subunit.

Authors:  O Bonny; A Chraibi; J Loffing; N F Jaeger; S Gründer; J D Horisberger; B C Rossier
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Aldosterone-related genetic effects in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

3.  Sgk: an old enzyme revisited.

Authors:  Nicolette Farman; Sheerazed Boulkroun; Nathalie Courtois-Coutry
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 4.  The molecular basis of blood pressure variation.

Authors:  Hakan R Toka; Jacob M Koshy; Ali Hariri
Journal:  Pediatr Nephrol       Date:  2012-07-05       Impact factor: 3.714

5.  Severe hyperkalemia is rescued by low-potassium diet in renal βENaC-deficient mice.

Authors:  Emilie Boscardin; Romain Perrier; Chloé Sergi; Marc Maillard; Johannes Loffing; Dominique Loffing-Cueni; Robert Koesters; Bernard Claude Rossier; Edith Hummler
Journal:  Pflugers Arch       Date:  2017-05-31       Impact factor: 3.657

Review 6.  Emerging Targets of Diuretic Therapy.

Authors:  C-J Cheng; A R Rodan; C-L Huang
Journal:  Clin Pharmacol Ther       Date:  2017-07-10       Impact factor: 6.875

Review 7.  Epithelial sodium channel, salt intake, and hypertension.

Authors:  Edith Hummler
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

8.  Mineralocorticoid receptor p.I180V polymorphism: association with body mass index and LDL-cholesterol levels.

Authors:  F L Fernandes-Rosa; A C Bueno; R Molina de Souza; M de Castro; J Ernesto dos Santos; M C Foss; M-C Zennaro; H Bettiol; M A Barbieri; S R Antonini
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

9.  Transient Pseudohypoaldosteronism due to Urinary Tract Infection in Infancy: A Report of 4 Cases.

Authors:  Radha Nandagopal; Priya Vaidyanathan; Paul Kaplowitz
Journal:  Int J Pediatr Endocrinol       Date:  2009-05-21

10.  Autosomal dominant pseudohypoaldosteronism type 1 with a novel splice site mutation in MR gene.

Authors:  Kyoko Kanda; Kandai Nozu; Naoki Yokoyama; Ichiro Morioka; Akihiro Miwa; Yuya Hashimura; Hiroshi Kaito; Kazumoto Iijima; Masafumi Matsuo
Journal:  BMC Nephrol       Date:  2009-11-14       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.